{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:46Z","timestamp":1793145286060,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04543-y","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:04:14Z","timestamp":1785747854000},"page":"2774-2785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The next generation of antibody\u2013drug conjugates"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-2900","authenticated-orcid":false,"given":"F.","family":"Mosele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Detappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"4543_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401, 1773\u20131785 (2023).","journal-title":"Lancet"},{"key":"4543_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4543_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255\u20131263 (2022).","journal-title":"Cancer Cell"},{"key":"4543_CR4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"4543_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00869-w","author":"A Zippelius","year":"2025","unstructured":"Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P. & Thurber, G. M. Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. Nat. Rev. Cancer https:\/\/doi.org\/10.1038\/s41568-025-00869-w (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"4543_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327\u2013344 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4543_CR7","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1200\/JCO.2025.43.16_suppl.3035","volume":"43","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. Results from a phase 1\/2 study of 7MW3711: a novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors. J. Clin. Oncol. 43, 3035 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Final results from the randomized phase III ASCENT clinical irial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J. Clin. Oncol. 42, 1738\u20131744 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR9","first-page":"2081\u20132099","volume":"85","author":"Q Wei","year":"2025","unstructured":"Wei, Q. et al. Perivascular niche-resident alveolar macrophages confer interstitial pneumonitis related to trastuzumab deruxtecan. Cancer Res. 85, 2081\u20132099 (2025).","journal-title":"Cancer Res."},{"key":"4543_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1535-7163.MCT-24-0267","volume":"24","author":"S Koganemaru","year":"2025","unstructured":"Koganemaru, S. et al. Potential mechanisms of interstitial lung disease induced by antibody\u2013drug conjugates based on quantitative analysis of drug distribution. Mol. Cancer Ther. 24, 242\u2013250 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","volume":"78","author":"C Cilliers","year":"2018","unstructured":"Cilliers, C., Menezes, B., Nessler, I., Linderman, J. & Thurber, G. M. Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival. Cancer Res. 78, 758\u2013768 (2018).","journal-title":"Cancer Res."},{"key":"4543_CR12","doi-asserted-by":"publisher","first-page":"eadk1894","DOI":"10.1126\/sciadv.adk1894","volume":"10","author":"B Rubahamya","year":"2024","unstructured":"Rubahamya, B., Dong, S. & Thurber, G. M. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci. Adv. 10, eadk1894 (2024).","journal-title":"Sci. Adv."},{"key":"4543_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2025.101437","volume":"24","author":"JR Thorup","year":"2025","unstructured":"Thorup, J. R. et al. Microscaled cell surface proteomics for cryo-preserved cells and tissue samples. Mol. Cell. Proteomics 24, 101437 (2025).","journal-title":"Mol. Cell. Proteomics"},{"key":"4543_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41416-025-03126-x","volume":"133","author":"A Shimauchi","year":"2025","unstructured":"Shimauchi, A. et al. Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations. Br. J. Cancer 133, 976\u2013985 (2025).","journal-title":"Br. J. Cancer"},{"key":"4543_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/carcin\/bgs128","volume":"33","author":"MM Sak","year":"2012","unstructured":"Sak, M. M. et al. The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner. Carcinogenesis 33, 1031\u20131039 (2012).","journal-title":"Carcinogenesis"},{"key":"4543_CR16","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-17-2391","volume":"77","author":"NG Caculitan","year":"2017","unstructured":"Caculitan, N. G. et al. Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates. Cancer Res. 77, 7027\u20137037 (2017).","journal-title":"Cancer Res."},{"key":"4543_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao, L. -C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."},{"key":"4543_CR18","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson, H. K. et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426\u20134433 (2006).","journal-title":"Cancer Res."},{"key":"4543_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1021\/bc025536j","volume":"13","author":"GM Dubowchik","year":"2002","unstructured":"Dubowchik, G. M. et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13, 855\u2013869 (2002).","journal-title":"Bioconjug. Chem."},{"key":"4543_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molonc.2013.08.011","volume":"8","author":"K von Schwarzenberg","year":"2014","unstructured":"von Schwarzenberg, K. et al. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. Mol. Oncol. 8, 9\u201319 (2014).","journal-title":"Mol. Oncol."},{"key":"4543_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107, 1039\u20131046 (2016).","journal-title":"Cancer Sci."},{"key":"4543_CR22","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata, T. N. et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol. Cancer Ther. 17, 1494\u20131503 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR23","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli, B. et al. Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial. Nat. Med. 31, 3492\u20133503 (2025).","journal-title":"Nat. Med."},{"key":"4543_CR24","doi-asserted-by":"publisher","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02478-2 (2023).","DOI":"10.1038\/s41591-023-02478-2"},{"key":"4543_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.ccell.2026.03.017","volume":"44","author":"D Planchard","year":"2022","unstructured":"Planchard, D. et al. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell 44, 1147\u20131159.e6 (2022).","journal-title":"Cancer Cell"},{"key":"4543_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0647","author":"W Chen","year":"2025","unstructured":"Chen, W. et al. Trastuzumab deruxtecan (T-DXd) resistance via loss of HER2 expression and binding. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0647 (2025).","journal-title":"Cancer Discov."},{"key":"4543_CR27","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates, J. T. et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11, 2436\u20132445 (2021).","journal-title":"Cancer Discov."},{"key":"4543_CR28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","volume":"31","author":"RO Abelman","year":"2025","unstructured":"Abelman, R. O. et al. TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer. Clin. Cancer Res. 31, 1966\u20131974 (2025).","journal-title":"Clin. Cancer Res."},{"key":"4543_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00868-y","volume":"12","author":"GW Sledge","year":"2025","unstructured":"Sledge, G. W. et al. Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. NPJ Breast Cancer 12, 1 (2025).","journal-title":"NPJ Breast Cancer"},{"key":"4543_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser, N. E. et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat. Commun. 14, 1394 (2023).","journal-title":"Nat. Commun."},{"key":"4543_CR31","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","volume":"15","author":"BECG de Goeij","year":"2016","unstructured":"de Goeij, B. E. C. G. et al. Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63. Mol. Cancer Ther. 15, 2688\u20132697 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","volume":"16","author":"J Andreev","year":"2017","unstructured":"Andreev, J. et al. Bispecific antibodies and antibody\u2013drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol. Cancer Ther. 16, 681\u2013693 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR33","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu, Y., Wang, Z. & Wang, Y. Bispecific antibody drug conjugates: making 1+1>2. Acta Pharm. Sin. B 14, 1965\u20131986 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"4543_CR34","doi-asserted-by":"publisher","first-page":"104874","DOI":"10.1016\/j.esmoop.2025.104874","volume":"10","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. 302MO Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic breast cancer (BC). ESMO Open 10, 104874 (2025).","journal-title":"ESMO Open"},{"key":"4543_CR35","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","volume":"21","author":"M Rigby","year":"2022","unstructured":"Rigby, M. et al. BT8009; a nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors. Mol. Cancer Ther. 21, 1747\u20131756 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR36","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1200\/JCO-25-00559","volume":"43","author":"C Baldini","year":"2025","unstructured":"Baldini, C. et al. First-in-human, phase I\/II dose escalation and expansion study of zelenectide pevedotin in patients with advanced solid tumors: results from monotherapy dose escalation. J. Clin. Oncol. 43, 3728\u20133738 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR37","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","volume":"67","author":"TT Dean","year":"2024","unstructured":"Dean, T. T., Jel\u00fa-Reyes, J., Allen, A. C. & Moore, T. W. Peptide\u2013drug conjugates: an emerging direction for the next generation of peptide therapeutics. J. Med. Chem. 67, 1641\u20131661 (2024).","journal-title":"J. Med. Chem."},{"key":"4543_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4543_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrc2364","volume":"8","author":"E Kritikou","year":"2008","unstructured":"Kritikou, E. Warburg effect revisited. Nat. Rev. Cancer 8, 247 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"4543_CR40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020606118","volume":"118","author":"HW Chang","year":"2021","unstructured":"Chang, H. W. et al. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches. Proc. Natl Acad. Sci. USA 118, e2020606118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4543_CR41","doi-asserted-by":"publisher","first-page":"2505092","DOI":"10.1080\/19420862.2025.2505092","volume":"17","author":"FR Brennan","year":"2025","unstructured":"Brennan, F. R. et al. Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies. mAbs 17, 2505092 (2025).","journal-title":"mAbs"},{"key":"4543_CR42","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody\u2013drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641\u2013661 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4543_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter, P. J. & Lazar, G. A. Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019. Nat. Rev. Drug Discov. 17, 197\u2013223 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4543_CR44","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/D0CS00310G","volume":"50","author":"SJ Walsh","year":"2021","unstructured":"Walsh, S. J. et al. Site-selective modification strategies in antibody\u2013drug conjugates. Chem. Soc. Rev. 50, 1305\u20131353 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"4543_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-62703-541-5_11","volume":"1045","author":"S Bhakta","year":"2013","unstructured":"Bhakta, S., Raab, H. & Junutula, J. R. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers. Methods Mol. Biol. 1045, 189\u2013203 (2013).","journal-title":"Methods Mol. Biol."},{"key":"4543_CR46","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733\u2013735 (2015).","journal-title":"Nat. Biotechnol."},{"key":"4543_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41587-025-02987-0","volume":"44","author":"C Sheridan","year":"2026","unstructured":"Sheridan, C. Now with oligos: antibody\u2013oligonucleotide conjugates are the new drug modality to watch. Nat. Biotechnol. 44, 3\u20135 (2026).","journal-title":"Nat. Biotechnol."},{"key":"4543_CR48","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1535-7163.MCT-16-0038","volume":"15","author":"PJ Burke","year":"2016","unstructured":"Burke, P. J. et al. Development of novel quaternary ammonium linkers for antibody\u2013drug conjugates. Mol. Cancer Ther. 15, 938\u2013945 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/17425247.2019.1645118","volume":"16","author":"E Merkul","year":"2019","unstructured":"Merkul, E. et al. First platinum(II)-based metal-organic linker technology (Lx\u00ae) for a plug-and-play development of antibody-drug conjugates (ADCs). Expert Opin. Drug Deliv. 16, 783\u2013793 (2019).","journal-title":"Expert Opin. Drug Deliv."},{"key":"4543_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04982-3","volume":"9","author":"Y Anami","year":"2018","unstructured":"Anami, Y. et al. Glutamic acid\u2013valine\u2013citrulline linkers ensure stability and efficacy of antibody\u2013drug conjugates in mice. Nat. Commun. 9, 2512 (2018).","journal-title":"Nat. Commun."},{"key":"4543_CR51","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh, J. D., Isidro-Llobet, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody\u2013drug conjugates. Chem. Soc. Rev. 48, 4361\u20134374 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"4543_CR52","doi-asserted-by":"publisher","first-page":"175883592413094","DOI":"10.1177\/17588359241309461","volume":"17","author":"D Izzo","year":"2025","unstructured":"Izzo, D. et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Ther. Adv. Med. Oncol. 17, 17588359241309461 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"4543_CR53","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1158\/1538-7445.AM2023-2635","volume":"83","author":"RA Carr","year":"2023","unstructured":"Carr, R. A. et al. N-myristolytransferase (NMT) inhibitors as novel potent payloads for antibody drug conjugates. Cancer Res. 83, 2635 (2023).","journal-title":"Cancer Res."},{"key":"4543_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman, S. E. et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat. Cancer 2, 18\u201333 (2021).","journal-title":"Nat. Cancer"},{"key":"4543_CR55","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","volume":"22","author":"I Primac","year":"2025","unstructured":"Primac, I., Tabury, K., Tasdogan, A., Baatout, S. & Herrmann, K. The molecular blueprint of targeted radionuclide therapy. Nat. Rev. Clin. Oncol. 22, 869\u2013894 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4543_CR56","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1158\/1535-7163.MCT-18-0643","volume":"17","author":"CS Neumann","year":"2018","unstructured":"Neumann, C. S. et al. Targeted delivery of cytotoxic NAMPT inhibitors using antibody\u2013drug conjugates. Mol. Cancer Ther. 17, 2633\u20132642 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR57","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1021\/acs.bioconjchem.7b00785","volume":"29","author":"D Su","year":"2018","unstructured":"Su, D. et al. Modulating antibody\u2013drug conjugate payload metabolism by conjugation site and linker modification. Bioconjug. Chem. 29, 1155\u20131167 (2018).","journal-title":"Bioconjug. Chem."},{"key":"4543_CR58","doi-asserted-by":"publisher","first-page":"8449","DOI":"10.1158\/1078-0432.CCR-05-1224","volume":"11","author":"LM Smith","year":"2005","unstructured":"Smith, L. M., Willmore, E., Austin, C. A. & Curtin, N. J. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. 11, 8449\u20138457 (2005).","journal-title":"Clin. Cancer Res."},{"key":"4543_CR59","doi-asserted-by":"publisher","first-page":"e2100456","DOI":"10.1200\/PO.21.00456","volume":"6","author":"TA Yap","year":"2022","unstructured":"Yap, T. A. et al. Phase Ib SEASTAR study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes. JCO Precis. Oncol. 6, e2100456 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"4543_CR60","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1158\/1538-7445.AM2025-2870","volume":"85","author":"G Yin","year":"2025","unstructured":"Yin, G. et al. Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtubule inhibitors or PARP inhibitors. Cancer Res. 85, 2870 (2025).","journal-title":"Cancer Res."},{"key":"4543_CR61","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1021\/acs.bioconjchem.5c00239","volume":"36","author":"W Sun","year":"2025","unstructured":"Sun, W. et al. SPARC: a multipayload ADC architecture for programmable drug combinations. Bioconjug. Chem. 36, 2158\u20132171 (2025).","journal-title":"Bioconjug. Chem."},{"key":"4543_CR62","unstructured":"Sutro Biopharma. Dual payload ADCs to overcome resistance. https:\/\/www.sutrobio.com\/wp-content\/uploads\/2026\/02\/2026-World-ADC_HP-Gerber_Plenary_Final.pdf (2026)."},{"key":"4543_CR63","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/1535-7163.MCT-25-0101","volume":"24","author":"S Abdelhamed","year":"2025","unstructured":"Abdelhamed, S. et al. PF-08046032: a novel, investigational CD25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced malignant tumors. Mol. Cancer Ther. 24, 963\u2013975 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR64","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1039\/D2CS00446A","volume":"51","author":"N Ashman","year":"2022","unstructured":"Ashman, N., Bargh, J. D. & Spring, D. R. Non-internalising antibody\u2013drug conjugates. Chem. Soc. Rev. 51, 9182\u20139202 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"4543_CR65","doi-asserted-by":"publisher","first-page":"S591","DOI":"10.1016\/j.annonc.2025.08.1534","volume":"36","author":"GM Cote","year":"2025","unstructured":"Cote, G. M. et al. 965P First- in- human study of the first-in-class non-cellular targeting antibody-drug conjugate (ADC), Micvotabart pelidotin (MICVO), in patients (pts) with select solid tumors. Ann. Oncol. 36, S591\u2013S592 (2025).","journal-title":"Ann. Oncol."},{"key":"4543_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19498-y","volume":"11","author":"G Lu","year":"2020","unstructured":"Lu, G. et al. Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates. Nat. Commun. 11, 5667 (2020).","journal-title":"Nat. Commun."},{"key":"4543_CR67","doi-asserted-by":"publisher","first-page":"101792","DOI":"10.1016\/j.xcrm.2024.101792","volume":"5","author":"A Gupta","year":"2024","unstructured":"Gupta, A. et al. EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep. Med. 5, 101792 (2024).","journal-title":"Cell Rep. Med."},{"key":"4543_CR68","doi-asserted-by":"publisher","first-page":"175883592513854","DOI":"10.1177\/17588359251385410","volume":"17","author":"DS-W Tan","year":"2025","unstructured":"Tan, D. S. -W. et al. TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib. Ther. Adv. Med. Oncol. 17, 17588359251385410 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"4543_CR69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2016.08.026","volume":"382","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 382, 176\u2013185 (2016).","journal-title":"Cancer Lett."},{"key":"4543_CR70","doi-asserted-by":"publisher","first-page":"121272","DOI":"10.1016\/j.ijpharm.2021.121272","volume":"610","author":"JR McCombs","year":"2021","unstructured":"McCombs, J. R., Chang, H. P., Shah, D. K. & Owen, S. C. Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy. Int. J. Pharm. 610, 121272 (2021).","journal-title":"Int. J. Pharm."},{"key":"4543_CR71","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/jpet.113.210146","volume":"349","author":"J Murai","year":"2014","unstructured":"Murai, J. et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J. Pharmacol. Exp. Ther. 349, 408\u2013416 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"4543_CR72","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","volume":"21","author":"A Zimmermann","year":"2022","unstructured":"Zimmermann, A. et al. A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies. Mol. Cancer Ther. 21, 859\u2013870 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR73","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1538-7445.AM2025-2905","volume":"85","author":"HM Robinson","year":"2025","unstructured":"Robinson, H. M. et al. Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors. Cancer Res. 85, 2905 (2025).","journal-title":"Cancer Res."},{"key":"4543_CR74","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.2024.42.16_suppl.1102","volume":"42","author":"RO Abelman","year":"2024","unstructured":"Abelman, R. O. et al. Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): results from a phase II study. J. Clin. Oncol. 42, 1102 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR75","doi-asserted-by":"publisher","first-page":"P2-08\u201327","DOI":"10.1158\/1557-3265.SABCS24-P2-08-27","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli, B. et al. Abstract P2-08-27: ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd) monotherapy & combinations in patients (pts) with inoperable advanced breast cancer (ABC) following progression on trastuzumab deruxtecan (T-DXd). Clin. Cancer Res. 31, P2-08\u201327 (2025).","journal-title":"Clin. Cancer Res."},{"key":"4543_CR76","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","volume":"29","author":"ML Abel","year":"2023","unstructured":"Abel, M. L. et al. Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial. Clin. Cancer Res. 29, 3603\u20133611 (2023).","journal-title":"Clin. Cancer Res."},{"key":"4543_CR77","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.2025.43.16_suppl.3037","volume":"43","author":"R Lin","year":"2025","unstructured":"Lin, R. et al. First-in-human trial of SYS6010 combined with SYH2051 in patients with advanced gastrointestinal tumors. J. Clin. Oncol. 43, 3037 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR78","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1038\/s41388-019-0965-5","volume":"38","author":"DH Ki","year":"2019","unstructured":"Ki, D. H., Oppel, F., Durbin, A. D. & Look, A. T. Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. Oncogene 38, 6585\u20136598 (2019).","journal-title":"Oncogene"},{"key":"4543_CR79","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","volume":"21","author":"O Cabaud","year":"2022","unstructured":"Cabaud, O. et al. Overcoming resistance to anti-nectin-4 antibody-drug conjugate. Mol. Cancer Ther. 21, 1227\u20131235 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR80","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen, R. et al. Inhibition of MDR1 overcomes resistance to brentuximab vedotin in hodgkin lymphoma. Clin. Cancer Res. 26, 1034\u20131044 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4543_CR81","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1158\/1538-7445.AM2025-7148","volume":"85","author":"S Siena","year":"2025","unstructured":"Siena, S. et al. Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02). Cancer Res. 85, 7148 (2025).","journal-title":"Cancer Res."},{"key":"4543_CR82","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3892\/ijmm.2025.5507","volume":"55","author":"R Fu","year":"2025","unstructured":"Fu, R. et al. A novel and promising therapeutic approach for treating pancreatic cancer: Nectin\u20114\u2011targeted antibody\u2011drug conjugates alone or combined with autophagy inhibitors. Int. J. Mol. Med. 55, 66 (2025).","journal-title":"Int. J. Mol. Med."},{"key":"4543_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06665-y","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE. Cell Death Dis. 15, 293 (2024).","journal-title":"Cell Death Dis."},{"key":"4543_CR84","doi-asserted-by":"publisher","first-page":"117550","DOI":"10.1016\/j.biopha.2024.117550","volume":"180","author":"C Xu","year":"2024","unstructured":"Xu, C. et al. Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer. Biomed. Pharmacother. 180, 117550 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"4543_CR85","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41420-024-02167-0","volume":"10","author":"W Xue","year":"2024","unstructured":"Xue, W. et al. Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer. Cell Death Discov. 10, 393 (2024).","journal-title":"Cell Death Discov."},{"key":"4543_CR86","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4543_CR87","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","volume":"394","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke, C. et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N. Engl. J. Med. 394, 1257\u20131269 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4543_CR88","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney, S. M. et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N. Engl. J. Med. 394, 354\u2013366 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4543_CR89","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.ccell.2024.11.005","volume":"42","author":"I-M Launonen","year":"2024","unstructured":"Launonen, I. -M. et al. Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. Cancer Cell 42, 2045\u20132063 (2024).","journal-title":"Cancer Cell"},{"key":"4543_CR90","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1200\/JCO.2024.42.16_suppl.1085","volume":"42","author":"N Mai","year":"2024","unstructured":"Mai, N. et al. Real world outcomes of sequential ADC therapy in metastatic breast cancer: patients treated with sacituzumab govitecan and trastuzumab deruxtecan. J. Clin. Oncol. 42, 1085 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR91","doi-asserted-by":"publisher","first-page":"PS08-02","DOI":"10.1158\/1538-7445.SABCS23-PS08-02","volume":"84","author":"F Poumeaud","year":"2024","unstructured":"Poumeaud, F. et al. Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study. Cancer Res. 84, PS08-02 (2024).","journal-title":"Cancer Res."},{"key":"4543_CR92","first-page":"TPS1123","volume":"42","author":"D Tripathy","year":"2024","unstructured":"Tripathy, D. et al. ACE-BREAST-03: a phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd). J. Clin. Oncol. 42, TPS1123 (2024).","journal-title":"Clin. Oncol."},{"key":"4543_CR93","doi-asserted-by":"publisher","first-page":"103067","DOI":"10.1016\/j.ctrv.2025.103067","volume":"142","author":"LFC de Almeida","year":"2026","unstructured":"de Almeida, L. F. C. et al. Sequencing antibody-drug conjugates in metastatic breast cancer: a systematic review. Cancer Treat. Rev. 142, 103067 (2026).","journal-title":"Cancer Treat. Rev."},{"key":"4543_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00748-5","volume":"11","author":"LA Huppert","year":"2025","unstructured":"Huppert, L. A. et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ Breast Cancer 11, 34 (2025).","journal-title":"NPJ Breast Cancer"},{"key":"4543_CR95","doi-asserted-by":"publisher","first-page":"S1153","DOI":"10.1016\/j.annonc.2024.08.2080","volume":"35","author":"BA McGregor","year":"2024","unstructured":"McGregor, B. A. et al. 1994P Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in \u2265 second line in metastatic urothelial carcinoma (mUC). Ann. Oncol. 35, S1153\u2013S1154 (2024).","journal-title":"Ann. Oncol."},{"key":"4543_CR96","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1538-7445.AM2025-5993","volume":"85","author":"Y-HC Tan","year":"2025","unstructured":"Tan, Y. -H. C. et al. Abstract 5993: Identification of predictive biomarkers of response to ADCs by HTS of highly molecularly characterized panels of patient-derived organoids (PDOs). Cancer Res. 85, 5993 (2025).","journal-title":"Cancer Res."},{"key":"4543_CR97","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MC Garassino","year":"2024","unstructured":"Garassino, M. C. et al. PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01. J. Thorac. Oncol. 19, S2\u2013S3 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"4543_CR98","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ijc.35498","volume":"157","author":"K Niedermayer","year":"2025","unstructured":"Niedermayer, K. et al. Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients. Int. J. Cancer 157, 1465\u20131480 (2025).","journal-title":"Int. J. Cancer"},{"key":"4543_CR99","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/ijgc-2023-004483","volume":"33","author":"Z Alizzi","year":"2023","unstructured":"Alizzi, Z. et al. Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes. Int. J. Gynecol. Cancer 33, 1427\u20131433 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"4543_CR100","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","volume":"29","author":"SC Baca","year":"2023","unstructured":"Baca, S. C. et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat. Med. 29, 2737\u20132741 (2023).","journal-title":"Nat. Med."},{"key":"4543_CR101","doi-asserted-by":"publisher","first-page":"B094","DOI":"10.1158\/1535-7163.TARG-25-B094","volume":"24","author":"M Hornsveld","year":"2025","unstructured":"Hornsveld, M. et al. Modelling ADC sensitivity and mode-of-action in human cancer derived organoids. Mol. Cancer Ther. 24, B094 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"4543_CR102","doi-asserted-by":"publisher","first-page":"LBA3000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","volume":"41","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J. Clin. Oncol. 41, LBA3000 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR103","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck, N. et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat. Med. 30, 3717\u20133727 (2024).","journal-title":"Nat. Med."},{"key":"4543_CR104","doi-asserted-by":"publisher","first-page":"125430","DOI":"10.1016\/j.ijpharm.2025.125430","volume":"674","author":"Z Tang","year":"2025","unstructured":"Tang, Z. et al. Ultrasonic head-mounted device spatiotemporal opening blood\u2013brain barrier enhances the brain permeation of drugs for treatment of radiation-induced brain injury. Int. J. Pharm. 674, 125430 (2025).","journal-title":"Int. J. Pharm."},{"key":"4543_CR105","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4543_CR106","doi-asserted-by":"crossref","unstructured":"Vulsteke, C. et al. Perioperative enfortumab vedotin (EV) plus pembrolizumab in participants with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase 3 KEYNOTE-905 study. ESMO Congress 2025 Abstract LBA2 (2025).","DOI":"10.1016\/j.annonc.2025.09.124"},{"key":"4543_CR107","doi-asserted-by":"publisher","first-page":"S1556","DOI":"10.1016\/j.annonc.2025.09.021","volume":"36","author":"CE Geyer","year":"2025","unstructured":"Geyer, C. E. et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2\u2013positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. Ann. Oncol. 36, S1556\u2013S1557 (2025).","journal-title":"Ann. Oncol."},{"key":"4543_CR108","doi-asserted-by":"publisher","unstructured":"Harbeck, N. et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.019 (2025).","DOI":"10.1016\/j.annonc.2025.10.019"},{"key":"4543_CR109","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","volume":"394","author":"S Loibl","year":"2026","unstructured":"Loibl, S. et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N. Engl. J. Med. 394, 845\u2013857 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4543_CR110","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1182\/blood.2024027239","volume":"146","author":"U Gerdemann","year":"2025","unstructured":"Gerdemann, U. et al. A single dose of a CD137 antibody\u2013drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD. Blood 146, 1127\u20131141 (2025).","journal-title":"Blood"},{"key":"4543_CR111","doi-asserted-by":"crossref","unstructured":"Tolaney, S. M. et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N. Engl. J. Med. 394, 551\u2013562 (2025).","DOI":"10.1056\/NEJMoa2508668"},{"key":"4543_CR112","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","volume":"26","author":"KW Locke","year":"2019","unstructured":"Locke, K. W., Maneval, D. C. & LaBarre, M. J. ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 26, 98\u2013106 (2019).","journal-title":"Drug Deliv."},{"key":"4543_CR113","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","volume":"130","author":"RL Wasserman","year":"2012","unstructured":"Wasserman, R. L. et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol. 130, 951\u2013957 (2012).","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04543-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:57Z","timestamp":1786629717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04543-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":113,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4543"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04543-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M.: advisory for Novartis. Y.O.: honoraria from Daiichi Sankyo, Pfizer, Eli Lilly, AstraZeneca and Chugai. A.D.: shareholder and cofounder of Recobia Therapeutics, Theraguix and TherO2. J.C.S.: full-time employee and shareholder of Amgen. F.A.: research grants or advisory boards paid to institution (hospital) from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, BMS, Pfizer, Relay Therapeutics and Roche; Honorarium (self) from Relay Therapeutics, Lilly, AstraZeneca, Novartis, Daiichi Sankyo and Bicycle Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}